MHRA updates Guidance on Sourcing Medicines for the UK Market

Recommendation
21/22 May 2025
Munich, Germany
The UK Medicines & Healthcare Products Regulatory Agency (MHRA) has updated its guidance on sourcing medicines for the UK market.
The document, which was first published on 31 December 2020, provides information on sourcing medicines that can be supplied by holders of wholesale distributor authorisations (WDAs) based in the UK.
The guidance covers the following aspects:
- Importing authorised medicines into the UK from a source which is on the approved country for import list
- Importing human medicines from a country on the list – for use as a special medicinal product
- Procuring human medicines from a country on the list for export purposes
- Importing medicines from a country on the list for supply to the United Kingdom parallel import market
The latest updates, published on 30 December 2024, reflect the new UK-wide licensing arrangements for human medicines that came into effect from 01 January 2025 as part of the Windsor Framework.
The complete guidance is available on the MHRA website.
Related GMP News
11.03.2025USP Publishes Summary of Comments on Chapter <1079.2> Regarding Mean Kinetic Temperature (MKT)
11.03.2025EMA: No further Extension of GDP Certificates in 2025
11.03.2025Aide-Mémoires and Checklists in GDP Audits - Benefits and Risks
13.02.2025First GDP Non-Compliance Report of 2025: Data Integrity Issues at Hungarian Wholesaler